Monday, 25 June 2018
Latest news
Main » Revenue Estimates Analysis Of Allergan plc (AGN)

Revenue Estimates Analysis Of Allergan plc (AGN)

15 December 2017

Shelton Capital Management now owns 4,117 shares of the company's stock worth $844,000 after purchasing an additional 1,077 shares during the last quarter. Nomura Asset Management Co. MA's holdings, making the stock its 13th largest position. Cetera Investment Advisers' holdings in Allergan were worth $632,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 81.34% of the company's stock. Pathstone Family Office LLC lifted its holdings in shares of Allergan by 3,327.3% during the second quarter. A statistical measure of the dispersion of returns (volatility) for ATH producing salvation in Investors mouth, it has week volatility of 3.52% and for the month booked as 2.42%. LLC lifted its holdings in shares of Allergan by 334.8% during the second quarter.

Before trading, trader, investor or shareholder must have an eye on stock's historical performance. Finally, Gofen & Glossberg LLC IL increased its stake in shares of Allergan by 5.7% during the 3rd quarter. Vanguard Group Inc. raised its holdings in shares of Allergan by 2.2% in the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company's stock valued at $132,000 after purchasing an additional 7 shares during the last quarter.

AGN has been the topic of several recent analyst reports.

The price target set for the stock is $227.29 and this sets up an interesting set of potential movement for the stock, according to data from Finviz's Research. BidaskClub downgraded shares of Allergan from a "hold" rating to a "sell" rating in a report on Thursday, August 17th.

More news: Officials say illegal cooking started one of California's blazing wildfires

General Motors Company was covered by a number of analysts recently, 7 rated the stock as Buy, 7 rated Outperform, 9 rated Hold, 0 gave an Underperform and 0 rated sell. Mizuho reaffirmed a "buy" rating and set a $267.00 target price on shares of Allergan in a report on Monday, September 25th.

In other Allergan news, insider William Meury sold 11,807 shares of the business's stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

NanoViricides, Inc. (NNVC) stock moved with shift of -10.71% in the past week. The formula for calculating the price-earnings ratio for any stock is simple: the market value per share divided by the earnings per share (EPS). The disclosure for this sale can be found here. Insiders have acquired 17,630 shares of company stock valued at $2,890,057 in the last quarter. On a Monthly basis the stock is -0.20%. RBC Capital Markets maintained Allergan plc (NYSE:AGN) rating on Friday, July 14. Current trade price levels places AGN's stock about -34.10% away from the 52-week high and closed 5.73% away from the 52-week low. Its Average True Range (ATR) value figured out at 0.07.

The stock market possibly will oblige dedication of a person and lot of hard work.

More news: Share Activity Lifted for Amgen Inc. (AMGN)

Is Allergan plc (NYSE:AGN) Performing Well? The company reported $4.15 earnings per share for the quarter, beating the consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Net profit margin of Allergan plc (AGN) was recorded at -48.6 percent, operating profit margin was -65.7 percent, while gross profit margin stands at 86.6 percent. Allergan's revenue was up 11.4% compared to the same quarter a year ago. As a company has 40.24M shares outstanding and its current share price is $0.36, the market cap is $14.47M.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Morgan Stanley lowered shares of Allergan from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $284.00 to $228.00 in a research note on Wednesday, September 20th. The ex-dividend date was Tuesday, May 16th. Allergan PLC.'s dividend payout ratio is presently 9.63%.

Allergan declared that its board has approved a stock repurchase program on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & worldwide copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/15/allergan-plc-agn-stake-lowered-by-cetera-investment-advisers.html.

More news: Alexandre Lacazette set for Arsenal recall against Newcastle

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide.